Platelet Rich Plasma Information and Market Trend - Asia Pacific Industry Analysis, Size, Share, Growth and Forecast 2015 - 2023
"Platelet
Rich Plasma Market - Asia Pacific Industry Analysis, Size, Share,
Growth, Trends, and Forecast 2015 - 2023"
The Report covers current Industries Trends, Worldwide Analysis,
Global Forecast, Review, Share, Size, Growth, Effect.
Description-
This
report provides a comprehensive analysis of the platelet rich plasma
market in Asia Pacific considering various macro as well as
microeconomic factors such as regulations, applications of platelet
rich plasma, and advantages and disadvantages of type of platelet
rich plasma, and cost. The report studies the platelet rich plasma
market from four perspectives: type of platelet rich plasma, origin
of platelet rich plasma, application of platelet rich plasma, and
country wise market.
Get
Sample
Report
With TOC @
http://www.researchmoz.us/enquiry.php?type=S&repid=582313
Based
on the type of platelet rich plasma, the market in Asia Pacific has
been segmented into pure platelet rich plasma, leucocytes and
platelet rich plasma, and platelet rich fibrin.
Based
on origin, the market has been segmented into autologous platelet
rich plasma, allogeneic platelet rich plasma, and homologous platelet
rich plasma. In terms of the application of platelet rich plasma, the
market has been segmented into orthopedic surgery, cosmetic surgery,
general surgery, neurosurgery, and other surgeries. In terms of
country, the market has been studied for eleven major geographies:
Australia, the Philippines, China, India, Singapore, Thailand,
Malaysia, South Korea, Hong Kong, Taiwan, and Rest of Asia Pacific.
Additionally, each segment of the platelet rich plasma market has
been further subdivided into national markets.
The market size for each of the segments and
sub-segments mentioned above is provided in US$ Mn considering 2013
and 2014 as base years and forecast from 2015 to 2023. The forecast
model considers various factors such as number of surgeries, health
care expenditure of the country, advantages of the individual
segment, penetration of platelet rich plasma therapy in the country,
the cost of platelet rich plasma in various countries, and government
regulations. The research methodology is a blend of primary as well
as secondary market research, where market estimates based on desk
research are further refined considering inputs from expert
interviews.
This report on the platelet rich plasma market in
Asia Pacific also provides qualitative information on major players
in the market. It also includes details on current regulatory
policies for platelet rich plasma and devices. Major factors driving
and restraining the platelet rich plasma market are also discussed in
the report, while opportunities from the future perspective are also
mentioned. Furthermore, the platelet rich plasma market report
provides value chain analysis for comprehensive analysis. Porter’s
Five Forces Analysis will provide the idea of bargaining power of
buyers, bargaining power of suppliers, threat of new entrants in
platelet rich plasma market, threat of substitutes, and competitive
rivalry in platelet rich plasma market. Additionally, market share
analysis of the platelet rich plasma market in Asia Pacific provides
detailed information on current competitive landscape of the market.
Market attractiveness analysis provides information on most
attractive countries for platelet rich plasma.
Finally, the report profiles major players in the
platelet rich plasma market in Asia Pacific including Harvest
Technology, Arthrex, Inc., Stryker Corporation, Zimmer Biomet, DePuy
Synthes, AdiStem Ltd., Cesca Therapeutics, Inc., Exactech, Inc., and
Rmedica Co. Ltd. Each of the companies is profiled for parameters
such as company overview, financial overview, product portfolio,
business strategies, and recent developments. The report on the
platelet rich plasma market estimation and forecast comprises 128
slides and 68 graphs.
1. Introduction
1.1 Report Description
1.2 Research Methodology
1.3 Market Segmentation
1.1 Report Description
1.2 Research Methodology
1.3 Market Segmentation
2. Executive Summary
2.1 Market Snapshot
2.1 Market Snapshot
3. Asia Pacific Platelet Rich Plasma
Market Overview
3.1 Introduction
3.2 Value Chain Analysis
3.3 Regulatory Framework
3.4 Market Dynamics
3.4.1 Drivers
3.4.2 Restraints
3.4.3 Opportunities
3.5 Porter’s Five Force Analysis
3.5.1 Bargaining Power of Buyers
3.5.2 Bargaining Power of Suppliers
3.5.3 Threat of New Entrants
3.5.4 Threat of Substitutes
3.5.5 Competitive Rivalry
3.6 Market Attractiveness Analysis of the Asia Pacific Platelet Rich Plasma Market, by Country, 2014
3.7 Competitive Landscape: Market Share Analysis by Key Players, 2014 (Value, %)
3.1 Introduction
3.2 Value Chain Analysis
3.3 Regulatory Framework
3.4 Market Dynamics
3.4.1 Drivers
3.4.2 Restraints
3.4.3 Opportunities
3.5 Porter’s Five Force Analysis
3.5.1 Bargaining Power of Buyers
3.5.2 Bargaining Power of Suppliers
3.5.3 Threat of New Entrants
3.5.4 Threat of Substitutes
3.5.5 Competitive Rivalry
3.6 Market Attractiveness Analysis of the Asia Pacific Platelet Rich Plasma Market, by Country, 2014
3.7 Competitive Landscape: Market Share Analysis by Key Players, 2014 (Value, %)
4. Asia Pacific Platelet Rich Plasma
Market Revenue, by Type, 2013–2023 (US$ Mn)
4.1 Overview
4.2 Pure Platelet-Rich Plasma (P-PRP) Market Revenue, by Country, 2013–2023 (US$ Mn)
4.2.1 Australia
4.2.2 Philippines
4.2.3 China
4.2.4 India
4.2.5 Singapore
4.2.6 Thailand
4.2.7 Malaysia
4.2.8 Korea
4.2.9 Hong Kong
4.2.10 Taiwan
4.2.11 Rest of APAC (Indonesia, New Zealand, Vietnam, etc.)
4.3 Leukocyte-Rich Platelet-Rich Plasma (L-PRP)*
4.4 Pure Platelet-Rich Fibrin (P-PRF)/ Leukocyte-Rich Platelet-Rich Fibrin (L-PRF)*
4.1 Overview
4.2 Pure Platelet-Rich Plasma (P-PRP) Market Revenue, by Country, 2013–2023 (US$ Mn)
4.2.1 Australia
4.2.2 Philippines
4.2.3 China
4.2.4 India
4.2.5 Singapore
4.2.6 Thailand
4.2.7 Malaysia
4.2.8 Korea
4.2.9 Hong Kong
4.2.10 Taiwan
4.2.11 Rest of APAC (Indonesia, New Zealand, Vietnam, etc.)
4.3 Leukocyte-Rich Platelet-Rich Plasma (L-PRP)*
4.4 Pure Platelet-Rich Fibrin (P-PRF)/ Leukocyte-Rich Platelet-Rich Fibrin (L-PRF)*
5. Asia Pacific Platelet Rich Plasma
Market Revenue, by Origin, 2013–2023 (US$ Mn)
5.1 Overview
5.2 Autologous Platelet-Rich Plasma
5.2.1 Australia
5.2.2 Philippines
5.2.3 China
5.2.4 India
5.2.5 Singapore
5.2.6 Thailand
5.2.7 Malaysia
5.2.8 Korea
5.2.9 Hong Kong
5.2.10 Taiwan
5.2.11 Rest of APAC (Indonesia, New Zealand, Vietnam, etc.)
5.3 Allogeneic Platelet-Rich Plasma*
5.4 Homologous Platelet-Rich Plasma*
5.1 Overview
5.2 Autologous Platelet-Rich Plasma
5.2.1 Australia
5.2.2 Philippines
5.2.3 China
5.2.4 India
5.2.5 Singapore
5.2.6 Thailand
5.2.7 Malaysia
5.2.8 Korea
5.2.9 Hong Kong
5.2.10 Taiwan
5.2.11 Rest of APAC (Indonesia, New Zealand, Vietnam, etc.)
5.3 Allogeneic Platelet-Rich Plasma*
5.4 Homologous Platelet-Rich Plasma*
6. Asia Pacific Platelet Rich Plasma
Market Revenue, by Application, 2013–2023 (US$ Mn)
6.1 Overview
6.2 Orthopedic Surgery
6.2.1 Australia
6.2.2 Philippines
6.2.3 China
6.2.4 India
6.2.5 Singapore
6.2.6 Thailand
6.2.7 Malaysia
6.2.8 Korea
6.2.9 Hong Kong
6.2.10 Taiwan
6.2.11 Rest of APAC (Indonesia, New Zealand, Vietnam, etc.)
6.3 Cosmetic Surgery*
6.4 General Surgery*
6.5 Neurosurgery*
6.6 Other Surgeries (Urology, Cardiothoracic, Oral & Maxillofacial and Periodontal)*
6.1 Overview
6.2 Orthopedic Surgery
6.2.1 Australia
6.2.2 Philippines
6.2.3 China
6.2.4 India
6.2.5 Singapore
6.2.6 Thailand
6.2.7 Malaysia
6.2.8 Korea
6.2.9 Hong Kong
6.2.10 Taiwan
6.2.11 Rest of APAC (Indonesia, New Zealand, Vietnam, etc.)
6.3 Cosmetic Surgery*
6.4 General Surgery*
6.5 Neurosurgery*
6.6 Other Surgeries (Urology, Cardiothoracic, Oral & Maxillofacial and Periodontal)*
7. Asia Pacific Platelet Rich Plasma
Market Revenue, by Country, 2013–2023 (US$ Mn)
7.1 Overview
7.2 Australia
7.3 Philippines
7.4 China
7.5 India
7.6 Singapore
7.7 Thailand
7.8 Malaysia
7.9 Korea
7.10 Hong Kong
7.11 Taiwan
7.12 Rest of APAC (Indonesia, New Zealand, Vietnam, etc.)
7.1 Overview
7.2 Australia
7.3 Philippines
7.4 China
7.5 India
7.6 Singapore
7.7 Thailand
7.8 Malaysia
7.9 Korea
7.10 Hong Kong
7.11 Taiwan
7.12 Rest of APAC (Indonesia, New Zealand, Vietnam, etc.)
8. Recommendations
9. Company Profiles
9.1 AdiStem Ltd.
9.2 Arthrex, Inc.
9.3 Biomet, Inc.
9.4 Cesca Therapeutics, Inc.
9.5 DePuy Synthes, Inc.
9.6 Exactech, Inc.
9.7 Harvest Technologies Corp.
9.8 NeoGenesis Co. Ltd.
9.9 Rmedica Co. Ltd.
9.10 Stryker Corporation
9.11 Seawon Meditech
9.12 Others
9.1 AdiStem Ltd.
9.2 Arthrex, Inc.
9.3 Biomet, Inc.
9.4 Cesca Therapeutics, Inc.
9.5 DePuy Synthes, Inc.
9.6 Exactech, Inc.
9.7 Harvest Technologies Corp.
9.8 NeoGenesis Co. Ltd.
9.9 Rmedica Co. Ltd.
9.10 Stryker Corporation
9.11 Seawon Meditech
9.12 Others
Comments
Post a Comment